BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Panel Seeks Ban On Some Cox-2 Ads


10/19/2005 5:12:47 PM

A Food and Drug Administration advisory committee has recommended banning direct-to-consumer (DTC) advertising of cox-2 inhibitors after finding that the painkillers produced by Merck and Pfizer increased the risk of heart attacksand strokes. The FDA panel on Friday stopped short of banning Merck's Vioxx and Pfizer's Celebrex and Bextra but a majority recommended strong individually tailored -- black box -- warnings for the cardiovascular risk. A ban on cox-2 drugs DTC advertising was strongly urged by a consensus on the committee, which comprised 32 private medical experts. If a ban was not possible, the committee discussed regulatory measures including requiring advertisements devoted to risk warnings, or stronger placement of risk warnings in marketing.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->